Augmentation regimens for depression

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

When antidepressant therapy fails to ameliorate the cardinal features of depression - e.g., sleep disturbance, appetite disturbance, suicidality - the clinician must seek an alternate treatment strategy. Treatment nonresponse is usually defined as persistence of depression after 6 weeks of adequate doses as shown by plasma concentrations of antidepressant medication. After the clinician has reassessed the patient and, in particular, the diagnosis of major depression, two major options are available: (1) taper the current antidepressant and initiate a trial of an unrelated antidepressant or (2) potentiate the antidepressant effects of the current antidepressant with either thyroid hormone, usually T3, or lithium. This paper describes in detail the usefulness of these two adjuncts in potentiating the effects of antidepressants and in converting antidepressant medication nonresponders to responders. Other augmentation strategies are also briefly described, including the concurrent use of two antidepressants from different drug classes.

Original languageEnglish
Pages (from-to)21-27
Number of pages7
JournalJournal of Clinical Psychiatry
Volume52
Issue number5 SUPPL.
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Antidepressive Agents
Depression
Triiodothyronine
Appetite
Lithium
Sleep
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Augmentation regimens for depression. / Nemeroff, Charles.

In: Journal of Clinical Psychiatry, Vol. 52, No. 5 SUPPL., 01.01.1991, p. 21-27.

Research output: Contribution to journalArticle

@article{4f47d3fd16b649fbae20d620e203462e,
title = "Augmentation regimens for depression",
abstract = "When antidepressant therapy fails to ameliorate the cardinal features of depression - e.g., sleep disturbance, appetite disturbance, suicidality - the clinician must seek an alternate treatment strategy. Treatment nonresponse is usually defined as persistence of depression after 6 weeks of adequate doses as shown by plasma concentrations of antidepressant medication. After the clinician has reassessed the patient and, in particular, the diagnosis of major depression, two major options are available: (1) taper the current antidepressant and initiate a trial of an unrelated antidepressant or (2) potentiate the antidepressant effects of the current antidepressant with either thyroid hormone, usually T3, or lithium. This paper describes in detail the usefulness of these two adjuncts in potentiating the effects of antidepressants and in converting antidepressant medication nonresponders to responders. Other augmentation strategies are also briefly described, including the concurrent use of two antidepressants from different drug classes.",
author = "Charles Nemeroff",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "52",
pages = "21--27",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Augmentation regimens for depression

AU - Nemeroff, Charles

PY - 1991/1/1

Y1 - 1991/1/1

N2 - When antidepressant therapy fails to ameliorate the cardinal features of depression - e.g., sleep disturbance, appetite disturbance, suicidality - the clinician must seek an alternate treatment strategy. Treatment nonresponse is usually defined as persistence of depression after 6 weeks of adequate doses as shown by plasma concentrations of antidepressant medication. After the clinician has reassessed the patient and, in particular, the diagnosis of major depression, two major options are available: (1) taper the current antidepressant and initiate a trial of an unrelated antidepressant or (2) potentiate the antidepressant effects of the current antidepressant with either thyroid hormone, usually T3, or lithium. This paper describes in detail the usefulness of these two adjuncts in potentiating the effects of antidepressants and in converting antidepressant medication nonresponders to responders. Other augmentation strategies are also briefly described, including the concurrent use of two antidepressants from different drug classes.

AB - When antidepressant therapy fails to ameliorate the cardinal features of depression - e.g., sleep disturbance, appetite disturbance, suicidality - the clinician must seek an alternate treatment strategy. Treatment nonresponse is usually defined as persistence of depression after 6 weeks of adequate doses as shown by plasma concentrations of antidepressant medication. After the clinician has reassessed the patient and, in particular, the diagnosis of major depression, two major options are available: (1) taper the current antidepressant and initiate a trial of an unrelated antidepressant or (2) potentiate the antidepressant effects of the current antidepressant with either thyroid hormone, usually T3, or lithium. This paper describes in detail the usefulness of these two adjuncts in potentiating the effects of antidepressants and in converting antidepressant medication nonresponders to responders. Other augmentation strategies are also briefly described, including the concurrent use of two antidepressants from different drug classes.

UR - http://www.scopus.com/inward/record.url?scp=0025852252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025852252&partnerID=8YFLogxK

M3 - Article

C2 - 2030101

AN - SCOPUS:0025852252

VL - 52

SP - 21

EP - 27

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5 SUPPL.

ER -